Open AccessThis article is
- freely available
Prospects for the Use of ATR Inhibitors to Treat Cancer
Division of Oncology Research, College of Medicine, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USA
* Author to whom correspondence should be addressed.
Received: 31 March 2010; in revised form: 12 April 2010 / Accepted: 19 April 2010 / Published: 28 April 2010
Abstract: ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.
Keywords: Replication checkpoint; ATR; ATM; chemotherapy; Chk1
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Wagner, J.M.; Kaufmann, S.H. Prospects for the Use of ATR Inhibitors to Treat Cancer. Pharmaceuticals 2010, 3, 1311-1334.
Wagner JM, Kaufmann SH. Prospects for the Use of ATR Inhibitors to Treat Cancer. Pharmaceuticals. 2010; 3(5):1311-1334.
Wagner, Jill M.; Kaufmann, Scott H. 2010. "Prospects for the Use of ATR Inhibitors to Treat Cancer." Pharmaceuticals 3, no. 5: 1311-1334.